Grape King Bio Ltd

NT$80.50As of Sun 8 Nov 2026, 12:00 UTC
TWSE:1707Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (7.61%)
Div yield 7.45%
ROE 15.59%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.24
PE TTM 10.47
TSR TTM (31.13%)
Mkt cap NT$11.93B
ROIC 20.56%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$92
14.50%
97.54%
Hold 1|9|5|11|7
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
1.34
1.41
1.51
1.68
22.82%
16.63%
24.28%
23.64%
RevenueNT$B
1.208
1.226
1.292
1.275
(0.17%)
1.89%
5.76%
4.59%
Peers (US$360.2M)
Cap (US$)
PE
444.5M
17.80x
298.5M
10.62x
Capital
TTM
5Y
10Y
Leveragex
0.731
0.339
0.303
EBIT/Intx
0.942
1.192
0.925
Own earn%
(84.78)
15.16
37.18
Sh yield%
9.61
21.05
24.11
Owners
Insiders/Inst%
11.48
40.13
Short interest%
0.62
SBC / revenue%
3.73
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
24–32
$1 testx
—
Incr. ROIC%
4